CN118924896A - 阿尔茨海默病的治疗及预防方法 - Google Patents

阿尔茨海默病的治疗及预防方法 Download PDF

Info

Publication number
CN118924896A
CN118924896A CN202411217698.2A CN202411217698A CN118924896A CN 118924896 A CN118924896 A CN 118924896A CN 202411217698 A CN202411217698 A CN 202411217698A CN 118924896 A CN118924896 A CN 118924896A
Authority
CN
China
Prior art keywords
months
subject
relative
composition
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411217698.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·鲁特曼
C·J·斯万森
Y·张
S·达达
J·王
L·克拉默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN118924896A publication Critical patent/CN118924896A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411217698.2A 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法 Pending CN118924896A (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201862702659P 2018-07-24 2018-07-24
US62/702,659 2018-07-24
US201862749614P 2018-10-23 2018-10-23
US62/749,614 2018-10-23
US201962824162P 2019-03-26 2019-03-26
US62/824,162 2019-03-26
US201962846902P 2019-05-13 2019-05-13
US62/846,902 2019-05-13
US201962874684P 2019-07-16 2019-07-16
US62/874,684 2019-07-16
CN201980062781.8A CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法
PCT/US2019/043067 WO2020023530A2 (en) 2018-07-24 2019-07-23 Methods of treatment and prevention of alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980062781.8A Division CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Publications (1)

Publication Number Publication Date
CN118924896A true CN118924896A (zh) 2024-11-12

Family

ID=67551415

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980062781.8A Pending CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法
CN202411217698.2A Pending CN118924896A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201980062781.8A Pending CN112805031A (zh) 2018-07-24 2019-07-23 阿尔茨海默病的治疗及预防方法

Country Status (13)

Country Link
US (1) US20210324056A1 (enExample)
EP (1) EP3826674A2 (enExample)
JP (2) JP7541505B2 (enExample)
KR (1) KR20210039402A (enExample)
CN (2) CN112805031A (enExample)
AU (1) AU2019309938A1 (enExample)
BR (1) BR112021001272A2 (enExample)
CA (1) CA3107370A1 (enExample)
IL (3) IL280315B2 (enExample)
MX (1) MX2021000778A (enExample)
PH (1) PH12021500006A1 (enExample)
TW (1) TW202019471A (enExample)
WO (1) WO2020023530A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
EP4121007B1 (en) * 2020-03-20 2025-07-02 Eisai R&D Management Co., Ltd. High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
WO2022035758A1 (en) * 2020-08-12 2022-02-17 The Cleveland Clinic Foundation Bace1 inhibitor treatment for suppressing cytokine storm
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
EP4448005A1 (en) * 2021-12-17 2024-10-23 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023111618A1 (en) * 2021-12-17 2023-06-22 Eisai R&D Management Co., Ltd. Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
JP2025506389A (ja) * 2022-02-02 2025-03-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ｐ－タウ１８１レベルを使用した治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2016208353B2 (en) * 2007-10-17 2017-07-20 Janssen Alzheimer Immunotherapy Immunotherapy regimes dependent on ApoE status
JP4520533B2 (ja) 2008-01-18 2010-08-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合アミノジヒドロチアジン誘導体
EP2448968B1 (en) 2009-06-29 2021-01-27 BioArctic AB ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS
US20130084245A1 (en) * 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
RU2555526C2 (ru) 2010-02-26 2015-07-10 Байоарктик Ньюросайенс Аб Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий
CN103502231A (zh) 2011-01-21 2014-01-08 卫材R&D管理有限公司 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物
RS61717B1 (sr) 2014-07-10 2021-05-31 Bioarctic Ab Poboljšana antitela koja vezuju a-beta protofibril
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3405489A1 (en) * 2016-01-20 2018-11-28 Genentech, Inc. High dose treatments for alzheimer's disease
ES2939373T3 (es) * 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JP7116725B2 (ja) * 2016-10-27 2022-08-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物

Also Published As

Publication number Publication date
US20210324056A1 (en) 2021-10-21
KR20210039402A (ko) 2021-04-09
IL323583A (en) 2025-11-01
CA3107370A1 (en) 2020-01-30
CN112805031A (zh) 2021-05-14
WO2020023530A3 (en) 2020-03-12
EP3826674A2 (en) 2021-06-02
IL280315B2 (en) 2024-06-01
JP2024112859A (ja) 2024-08-21
IL310132A (en) 2024-03-01
JP2021532126A (ja) 2021-11-25
IL280315B1 (en) 2024-02-01
WO2020023530A2 (en) 2020-01-30
MX2021000778A (es) 2021-03-31
PH12021500006A1 (en) 2021-09-13
JP7541505B2 (ja) 2024-08-28
AU2019309938A1 (en) 2021-03-11
TW202019471A (zh) 2020-06-01
IL280315A (en) 2021-03-25
BR112021001272A2 (pt) 2021-04-27
IL310132B1 (en) 2025-11-01

Similar Documents

Publication Publication Date Title
CN118924896A (zh) 阿尔茨海默病的治疗及预防方法
CA2163966A1 (en) Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
JP2018111723A (ja) アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2024525559A (ja) アルツハイマー病治療用バイオマーカー
US20200330592A1 (en) Compositions and methods of treating alzheimer's and other amyloid related diseases
KR20190102181A (ko) 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
KR20240142535A (ko) P-tau181 수준을 사용한 치료 방법
CA3230148A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
EP4626918A1 (en) Methods of treatment using a tau pet level
RU2832167C2 (ru) Способы лечения и предупреждения болезни альцгеймера
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
BR122025003268A2 (pt) Métodos de tratamento e prevenção de doença de alzheimer
TW202518027A (zh) 抗微生物肽
CN118786141A (zh) 使用p-tau181水平的治疗方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118843

Country of ref document: HK